From Nasdaq: 2025-06-12 18:02:00

Novo Nordisk (NYSE: NVO) stock rose nearly 3% after reporting positive results from a late-stage clinical trial for an investigational weight-loss drug called amycretin. This drug is being advanced to a phase 3 study, with trials expected to begin in the first quarter of 2026. Amycretin is a GLP-1 agonist that also imitates another hormone called amylin, making it a potentially significant addition to the weight-loss drug market. The move marks a promising development for Novo Nordisk as it seeks to expand its portfolio beyond its popular drugs Wegovy and Ozempic.



Read more at Nasdaq: Why Novo Nordisk Stock Pumped Higher on Thursday